Breast cancer remains the most commonly diagnosed cancer among women globally and a leading cause of cancer-related mortality. While imaging-based screening programmes, such as mammography, have contributed to earlier detection, they present critical limitations. These include high false-positive rates, limited positive predictive value (~23%), and reduced sensitivity in women with dense breast tissue—factors that often result in unnecessary biopsies, overtreatment, psychological distress, and significant healthcare burden.

At VibraSpeX, we are redefining cancer screening through intelligent laser spectroscopy. Our proprietary platform integrates advanced vibrational laser spectroscopy with artificial intelligence to enable truly non-invasive analysis — free from harmful radiation and chemical reagents — of biofluids such as blood plasma and serum, supporting personalised, early cancer detection.